Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NADIM-ADJUVANT: Adjuvant Chemoimmunotherapy in Resected NSCLC
NCT04564157Phase 3Active, not recruiting
- Sponsor
- Fundación GECP
- Start
- Jan 2021
- Primary completion
- Apr 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fundación GECP. Primary endpoint: Disease-Free Survival at 60 months. Started Jan 2021; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04564157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564157.